Targeting GDNFs in cancer therapy presents several challenges. One major issue is the potential for off-target effects, given that GDNFs also play essential roles in normal neuronal function. Additionally, cancer cells can activate compensatory pathways to bypass inhibited GDNF signaling, reducing the effectiveness of targeted therapies. Therefore, combination therapies targeting multiple pathways are being explored to overcome these challenges.
